ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing
compound TIC10. ONC201 appears to act as a selective antagonist of the G protein …

ONC201 is the founding member of a novel class of anti-cancer compounds called
imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the …

The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein
quality control by degrading misfolded proteins. Using genetic and chemical approaches, …

… He then received 5 cycles of adjuvant temozolomide (dosed at 150–200 mg/m 2 daily for
5 consecutive days of every 28 day cycle) until radiographic progression was observed on a …

Drug target identification is a crucial step in development, yet is also among the most
complex. To address this, we develop BANDIT, a Bayesian machine-learning approach that …

Purpose: ONC201 is a small-molecule selective antagonist of the G protein–coupled
receptor DRD2 that is the founding member of the imipridone class of compounds. A first-in-human …

The objective of this analysis was to describe the pharmacokinetic characteristics of
anidulafungin in patients with serious fungal disease based on pharmacokinetic data collected …

Two open‐label studies assessed the effects of hepatic and renal impairment on anidulafungin
pharmacokinetics. A single 50‐mg dose was administered intravenously to subjects with …

Background ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the
blood–brain barrier. ONC201 efficacy has been shown in glioblastoma animal models and is …

Anti-cancer small molecule ONC201 upregulates the integrated stress response (ISR) and
acts as a dual inactivator of Akt/ERK, leading to TRAIL gene activation. ONC201 is under …